2017
Genetic Effects on the Correlation Structure of CVD Risk Factors Exome-Wide Data From a Ghanaian Population
Kodaman N, Sobota RS, Asselbergs FW, Oetjens MT, Moore JH, Brown NJ, Aldrich MC, Williams SM. Genetic Effects on the Correlation Structure of CVD Risk Factors Exome-Wide Data From a Ghanaian Population. Global Heart 2017, 12: 133-140. PMID: 28408189, PMCID: PMC5642993, DOI: 10.1016/j.gheart.2017.01.013.Peer-Reviewed Original ResearchConceptsPlasminogen activator inhibitor-1CVD risk factorsRisk factorsCardiovascular disease risk factorsDisease risk factorsHigh blood pressureActivator inhibitor-1Dissolution of thrombusArterial pressureBlood pressureMyocardial infarctionPlasma concentrationsStudy participantsGhanaian populationInhibitor-1Significant heterogeneityHeterogeneity of correlationAfrican AmericansGenetic variantsGenetic association studiesDirect role
2007
Aldosterone and end-organ damage
Marney AM, Brown NJ. Aldosterone and end-organ damage. Clinical Science 2007, 113: 267-278. PMID: 17683282, DOI: 10.1042/cs20070123.Peer-Reviewed Original ResearchConceptsMR antagonismBlood pressureEndothelial functionMyocardial infarctionGlucose homeostasisRapid non-genomic effectsEnd-organ damageImpairs endothelial functionNon-genomic effectsNon-genomic pathwaysResistant hypertensionAldosterone concentrationEndothelial dysfunctionRenal injuryDiabetic patientsMetabolic syndromeSleep apnoeaSubsequent fibrosisMR activationSodium retentionCardiac fibrosisCardiovascular remodellingBody of evidenceAldosteronePatients
2002
ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism
Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism. Hypertension 2002, 40: 859-865. PMID: 12468570, DOI: 10.1161/01.hyp.0000040264.15961.48.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood GlucoseBlood PressureDiureticsDose-Response Relationship, DrugDrug Therapy, CombinationFemaleHumansHydrochlorothiazideHypertensionInsulinInsulin ResistanceLosartanMaleMiddle AgedPlasminogen Activator Inhibitor 1RamiprilReceptor, Angiotensin, Type 1Renin-Angiotensin SystemSodium Chloride Symporter InhibitorsTissue Plasminogen ActivatorTreatment OutcomeConceptsPlasminogen activator inhibitor-1PAI-1 antigenAngiotensin type 1 receptor antagonismPlasma PAI-1 antigenAT1 receptor antagonismReceptor antagonismACE inhibitionAddition of ramiprilAngiotensin receptor antagonismWeeks of hydrochlorothiazideEffects of losartanPlasma PAI-1Activator inhibitor-1Aldosterone systemHypertensive subjectsBlood pressureFibrinolytic variablesMyocardial infarctionTPA antigenRisk factorsTreatment periodLosartanTPA activityAntigenInhibitor-1
1998
Effect of Activation and Inhibition of the Renin-Angiotensin System on Plasma PAI-1
Brown N, Agirbasli M, Williams G, Litchfield W, Vaughan D. Effect of Activation and Inhibition of the Renin-Angiotensin System on Plasma PAI-1. Hypertension 1998, 32: 965-971. PMID: 9856958, DOI: 10.1161/01.hyp.32.6.965.Peer-Reviewed Original ResearchMeSH KeywordsAdultAldosteroneAngiotensin-Converting Enzyme InhibitorsCatecholaminesCircadian RhythmCreatinineDiet, Sodium-RestrictedFibrinolysisHemodynamicsHumansHydrocortisoneIsoquinolinesMalePlasminogen Activator Inhibitor 1QuinaprilReninRenin-Angiotensin SystemSodiumSupine PositionTetrahydroisoquinolinesTissue Plasminogen ActivatorConceptsLow salt intakeRenin-angiotensin systemPAI-1 antigenPlasma renin activitySalt intakeACE inhibitionMyocardial infarctionTPA antigenFibrinolytic systemPAI-1Plasminogen activator inhibitor-1 activityTissue-type plasminogen activator antigenPAI-1 antigen concentrationsPAI-1 antigen levelsThrombotic cardiovascular eventsHigh salt intakeLeft ventricular dysfunctionRecurrent myocardial infarctionPlasminogen activator antigenInhibitor-1 activityPlasma PAI-1PAI-1 activityConcomitant ACE inhibitionCardiovascular eventsRenin activityAngiotensin-Converting Enzyme Inhibitors
Brown N, Vaughan D. Angiotensin-Converting Enzyme Inhibitors. Circulation 1998, 97: 1411-1420. PMID: 9577953, DOI: 10.1161/01.cir.97.14.1411.Peer-Reviewed Original ResearchConceptsACE inhibitorsVentricular dysfunctionMyocardial infarctionAngiotensin AT1 receptor antagonistAngiotensin converting enzyme (ACE) inhibitorsTissue-bound ACESystemic vascular resistanceCongestive heart failureAT1 receptor antagonistTreatment of hypertensionRoute of eliminationVascular resistanceCardiovascular mortalityDiabetic nephropathyEssential hypertensionHeart failureNatriuretic propertiesRenal diseaseVasoactive substancesAngiotensin IIReceptor antagonistHeart rateSide effectsEnzyme inhibitorsHypertrophic properties
1997
Plasminogen actiwator inhibitor type 1 in diabetes and hypertension
Litchfield W, Brown N, Vaughan D. Plasminogen actiwator inhibitor type 1 in diabetes and hypertension. Current Opinion In Endocrinology Diabetes And Obesity 1997, 4: 233-238. DOI: 10.1097/00060793-199706000-00009.Peer-Reviewed Original ResearchCardiovascular riskPAI-1Inhibitor type 1Type 1Elevated levelsIncreased cardiovascular riskRenin-angiotensin systemEndogenous fibrinolytic systemPlasminogen activator inhibitor type 1Activator inhibitor type 1Tissue plasminogen activatorHypertensive patientsEssential hypertensionMyocardial infarctionCardiovascular diseaseFibrinolytic systemHypertensionPlasminogen activatorStrong associationIncidenceRiskPrimary inhibitorHyperinsulinemiaHypertriglyceridemiaInfarction
1996
Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy
Hunley T, Julian B, Phillips J, Summar M, Yoshida H, Horn R, Brown N, Fogo A, Ichikawa I, Kon V. Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy. Kidney International 1996, 49: 571-577. PMID: 8821846, DOI: 10.1038/ki.1996.81.Peer-Reviewed Original ResearchConceptsRenin-angiotensin systemIgA nephropathyRenal functionDD genotypeMyocardial infarctionCardiovascular diseaseACE genotype frequenciesGene polymorphismsBiopsy-proven IgA nephropathyACE I/D polymorphismAGT 235TEnzyme deletion polymorphismNormal serum creatinineRenal disease progressionACE DD genotypeEnzyme gene polymorphismGenotype frequenciesI gene polymorphismStable creatinineAngiotensin systemSerum creatinineRenal statusVentricular hypertrophyCaucasian patientsRisk factors